Author: [AUTHOR] Published on 3/6/2025 12:00:00 AMThe scientific research community faces unprecedented threats that jeopardize the progress we've collectively achieved. Recent proposals to significantly reduce funding for the National Institutes of Health (NIH) have raised deep concerns among researchers and healthcare professionals nationwide. These proposed cuts, including capping indirect expenses at 15%, could severely impact essential medical research projects.
As a member of Research!America—a leading non-profit medical and health research advocacy alliance dedicated to advancing science, discovery, and innovation for better health—ASCPT is actively collaborating with more than 600 leading scientific, medical, and patient advocacy organizations to support sustained and increased NIH funding. In alignment with this commitment, recently ASCPT has co-signed a coalition letter organized by Research!America, addressed to Senate and House Appropriations leaders, urging them to prioritize NIH funding and preserve protections against cuts to reimbursement for NIH grantee facilities and administrative costs. You can view the letter here. This collective action underscores the critical role of NIH funding, which has contributed to 386 of the 387 new drugs approved by the FDA between 2000 and 2019 (Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry). Such a statistic highlights the profound impact of sustained investment in medical research on public health advancements.
ASCPT remains steadfast in our mission to support the field of clinical pharmacology and translational science and the broader scientific research community. We are committed to working alongside other like-minded organizations and our members to ensure that scientific discovery and innovation continue to thrive, ultimately leading to better health outcomes for all. Thank you for your continued dedication and support.
